THURSDAY, APRIL 11 - FRIDAY, APRIL 12
DAY 1: 1:40 - 5:20 PM | DAY 2: 8:30 AM - 3:40 PM (Back Bay Complex)

TS9C: Genome Editing with CRISPR: Towards Novel Research, Translational and Clinical Applications

DAY 1: THURSDAY

1:40 - 5:20 pm Seminar Sessions

DAY 2: FRIDAY

8:30 am - 3:40 pm Seminar Sessions

12:30 - 1:30 pm Lunch Provided

Refreshment Breaks also provided.

Instructor:

Serguei Kozlov, PhD, MBA, PMP, Principal Scientist/PM, Team Leader PTO, Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research (NCI)

Introduction:

This rigorous day and a half program compiled for specialists interested in applying genome editing technologies for both basic and translational research will comprehensively review the state-of-art information on gene editing strategies and applications in various areas, such as disease modelling, drug discovery and development. Beginning from introductory level basic technology aspects, key molecular features, strengths and shortcomings of CRISPR/Cas9 systems, the instructor will advance towards sharing in-depth knowledge related to virtually all facets of present day genome editing applications, such as constructing of cell culture based experimental platforms, engineering disease models for in vivo research supporting preclinical drug development workflows, rational design and functional screening of sgRNA libraries, application of CRISPR/Cas9 technology for diagnostic and therapeutic purposes and many others. The instructor will strive to achieve a balance between presenting theory information and conducting some practical tasks in exploring available digital resources for designing and enabling CRISPR/Cas9 studies, as well as assist in troubleshooting specific complex experimental scenarios and conduct Q&A sessions.

Topics to be Covered in the Seminar:

• Introduction into Genome Editing Technologies: from ZNF to TALEN to CRISPR/Cas9 to Base Editor Nucleases
• Specific Aspects of CRISPR Technology, Including:
• Biology of dsDNA Break Repair and Its Implications for CRISPR Experimental Designs
• Immunogenicity of CRISPR Reagents: Experimental Considerations
• nCas9 and dCas9/“nuclease-null” Isoforms of Editing Nucleases and Their Applications (CRISPRa, CRISPRi, precision epigenetic, chromosome localization, single base editor nucleases, etc.)
• Non-Cas9 Based Systems for DNA and RNA Editing
• CRISPR/Cas9 Bioinformatics and Experimental Design Resources
• Synopsis of Various Delivery Systems and Available Reagent Collections to Support CRISPR In Vivo and In Vitro Technology Applications
• CRISPR Technologies in Target Identification and Drug Screening
• Rational Design and Screening of CRISPR Libraries
• Development of Disease Models with CRISPR Technology for Translational Experimentation or Preclinical Drug Development
• Overview of Emerging Clinical and Diagnostic Applications for CRISPR/Cas9 Technology
• Final Discussion/Tips and Tricks Session
• Troubleshooting Specific Cases and Workshop Adjourn

Serguei Kozlov, PhD, MBA, PMP, Principal Scientist/PM, Team Leader PTO, Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research (NCI)

Internationally recognized expert in advanced methodologies for developing genetically and biologically engineered preclinical murine disease models for studies of the molecular mechanisms of carcinogenesis, tumor immune response, immune surveillance, and inflammation, mechanisms of drug resistance, implication of cancer stem cells, etc.; and to explore such models for preclinical drug development, disease systems analyses and biomarker discovery. Initiated, supervised, and successfully conducted multiple research projects and independent large-scale research and development programs aimed at investigation of molecular mechanisms governing carcinogenesis, biomarker discovery and preclinical drug evaluation in various mouse models. Oversee the preclinical operations at the Frederick National Laboratory Center for Advanced Preclinical Research – an innovative preclinical cancer modeling and drug development initiative based on genetically engineered murine models – with senior management responsibilities. Co-authored over 60 scientific papers, book chapters and original works in peer-reviewed journals.

What is a Training Seminar?

Each Training Seminar offers 1.5 Days of instruction with start and stop times for each day shown above and on the Event-at-a-Glance published in the onsite Program & Event Guide. Training Seminars will include morning and afternoon refreshment breaks, as applicable, and lunch will be provided to all registered attendees on the full day of the class.

Each person registered specifically for the training seminar will be provided with a hard copy handbook for the seminar in which they are registered. A limited number of additional handbooks will be available for other delegates who wish to attend the seminar, but after these have been distributed no additional books will be available.

Though CHI encourages track and symposia hopping between conference programs, we ask that Training Seminars not be disturbed once they have begun. In the interest of maintaining the highest quality learning environment for Training Seminar attendees, and because Seminars are conducted differently than conference programming, we ask that attendees commit to attending the entire program, and NOT engaging in track hopping, as to not disturb the hands-on style instruction being offered to the other participants.